New drug before surgery shows promise for hard-to-treat colon cancer
NCT ID NCT06686576
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called QL1706 given before surgery for people with a specific type of colon cancer (MSI-H/dMMR) that has not spread far. About 363 participants will receive either QL1706 or standard care. The goal is to see if QL1706 can eliminate more tumor tissue before surgery and improve long-term outcomes. Participants must have good organ function and no prior cancer treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLON CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Affiliated Cancer Hospital of Sun Yat-sen University
RECRUITINGGuangzhou, China
Contact